- |||||||||| niclosamide nasal spray (UNI91103) / UNION Therap, Institut Pasteur Korea, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Trial primary completion date: PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) - Mar 17, 2024
P2/3, N=5000, Recruiting,
Trial primary completion date: Jul 2023 --> Jul 2024
- |||||||||| niclosamide nasal spray (UNI91103) / UNION Therap, Institut Pasteur Korea, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Enrollment change, Trial completion date, Trial primary completion date: PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) - Mar 8, 2022
P2/3, N=5000, Recruiting,
Trial primary completion date: Jul 2023 --> Jul 2024 N=1500 --> 5000 | Trial completion date: Mar 2022 --> Oct 2024 | Trial primary completion date: Dec 2021 --> Jul 2023
- |||||||||| niclosamide nasal spray (UNI91103) / UNION Therap, Institut Pasteur Korea, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
New P2/3 trial: PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) - May 2, 2021
P2/3, N=1500, Recruiting,
|
